Adherium has announced the appointment of Jane Lapon as Head of Global Market Access & Reimbursement, where she will be responsible for ensuring reimbursement for the Hailie inhaler monitoring platform. Lapon was most recently VP of Global Market Access at Boston Scientific and has previously held executive positions in global market access roles at BTG (which was acquired by Boston Scientific in August 2019), Nordion, and Bristol-Myers Squibb.
Lapon will report to Adherium Chief Commercial Officer Mike Motion, whose appointment was announced by the company in November 2019, along with new CEO Peter Stratford.
Motion commented, “As we enter this commercialization growth phase, it was critical to enhance Adherium’s capabilities in market access. Obtaining reimbursement for the Hailie platform in our target markets, implementing payer-led strategies and developing our portfolio with payers in mind are all critical aspects of the commercial strategy. Jane brings a high caliber of expertise to enable effective execution of these strategies, and an impressive track record of obtaining reimbursement globally for a number of complex devices, drugs and first-in-class product. She is a valuable addition to the team.”
Lapon said, “I am pleased to be joining Adherium at such a critical point and look forward to leading market access efforts to further support commercial growth. The ultimate objective is to ensure that those patients who will benefit from the Hailie platform are able to access it – and I look forward to working with the team, our business partners and key stakeholders, to demonstrate the value of this technology to payers to enable that to happen.”
